[図1]

配列番号１：抗ＨＥＲ２抗体重鎖のアミノ酸配列

ＥＶＱＬＶＥＳＧＧＧＬＶＱＰＧＧＳＬＲＬＳＣＡＡＳＧＦＮＩＫＤＴＹＩＨＷＶＲ
ＱＡＰＧＫＧＬＥＷＶＡＲＩＹＰＴＮＧＹＴＲＹＡＤＳＶＫＧＲＦＴＩＳＡＤＴＳＫ
ＮＴＡＹＬＱＭＮＳＬＲＡＥＤＴＡＶＹＹＣＳＲＷＧＧＤＧＦＹＡＭＤＹＷＧＱＧＴ
ＬＶＴＶＳＳＡＳＴＫＧＰＳＶＦＰＬＡＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹ
ＦＰＥＰＶＴＶＳＷＮＳＧＡＬＴＳＧＶＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴ
ＶＰＳＳＳＬＧＴＱＴＹＩＣＮＶＮＨＫＰＳＮＴＫＶＤＫＫＶＥＰＫＳＣＤＫＴＨＴ
ＣＰＰＣＰＡＰＥＬＬＧＧＰＳＶＦＬＦＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶ
ＶＤＶＳＨＥＤＰＥＶＫＦＮＷＹＶＤＧＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲ
ＶＶＳＶＬＴＶＬＨＱＤＷＬＮＧＫＥＹＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡ
ＫＧＱＰＲＥＰＱＶＹＴＬＰＰＳＲＥＥＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩ
ＡＶＥＷＥＳＮＧＱＰＥＮＮＹＫＴＴＰＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳ
ＲＷＱＱＧＮＶＦＳＣＳＶＭＨＥＡＬＨＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

[図2]

配列番号２：抗ＨＥＲ２抗体軽鎖のアミノ酸配列

ＤＩＱＭＴＱＳＰＳＳＬＳＡＳＶＧＤＲＶＴＩＴＣＲＡＳＱＤＶＮＴＡＶＡＷＹＱＱ
ＫＰＧＫＡＰＫＬＬＩＹＳＡＳＦＬＹＳＧＶＰＳＲＦＳＧＳＲＳＧＴＤＦＴＬＴＩＳ
ＳＬＱＰＥＤＦＡＴＹＹＣＱＱＨＹＴＴＰＰＴＦＧＱＧＴＫＶＥＩＫＲＴＶＡＡＰＳ
ＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶＶＣＬＬＮＮＦＹＰＲＥＡＫＶＱＷＫＶＤＮ
ＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤＳＴＹＳＬＳＳＴＬＴＬＳＫＡＤＹＥＫＨＫ
ＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳＦＮＲＧＥＣ

[図3]

配列番号３：抗ＨＥＲ３抗体重鎖のアミノ酸配列

ＱＶＱＬＱＱＷＧＡＧＬＬＫＰＳＥＴＬＳＬＴＣＡＶＹＧＧＳＦＳＧＹＹＷＳＷＩＲ
ＱＰＰＧＫＧＬＥＷＩＧＥＩＮＨＳＧＳＴＮＹＮＰＳＬＫＳＲＶＴＩＳＶＥＴＳＫＮ
ＱＦＳＬＫＬＳＳＶＴＡＡＤＴＡＶＹＹＣＡＲＤＫＷＴＷＹＦＤＬＷＧＲＧＴＬＶＴ
ＶＳＳＡＳＴＫＧＰＳＶＦＰＬＡＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹＦＰＥ
ＰＶＴＶＳＷＮＳＧＡＬＴＳＧＶＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴＶＰＳ
ＳＳＬＧＴＱＴＹＩＣＮＶＮＨＫＰＳＮＴＫＶＤＫＲＶＥＰＫＳＣＤＫＴＨＴＣＰＰ
ＣＰＡＰＥＬＬＧＧＰＳＶＦＬＦＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶＶＤＶ
ＳＨＥＤＰＥＶＫＦＮＷＹＶＤＧＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲＶＶＳ
ＶＬＴＶＬＨＱＤＷＬＮＧＫＥＹＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡＫＧＱ
ＰＲＥＰＱＶＹＴＬＰＰＳＲＥＥＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩＡＶＥ
ＷＥＳＮＧＱＰＥＮＮＹＫＴＴＰＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳＲＷＱ
ＱＧＮＶＦＳＣＳＶＭＨＥＡＬＨＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

[図4]

配列番号４：抗ＨＥＲ３抗体軽鎖のアミノ酸配列

ＤＩＥＭＴＱＳＰＤＳＬＡＶＳＬＧＥＲＡＴＩＮＣＲＳＳＱＳＶＬＹＳＳＳＮＲＮＹ
ＬＡＷＹＱＱＮＰＧＱＰＰＫＬＬＩＹＷＡＳＴＲＥＳＧＶＰＤＲＦＳＧＳＧＳＧＴＤ
ＦＴＬＴＩＳＳＬＱＡＥＤＶＡＶＹＹＣＱＱＹＹＳＴＰＲＴＦＧＱＧＴＫＶＥＩＫＲ
ＴＶＡＡＰＳＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶＶＣＬＬＮＮＦＹＰＲＥＡＫＶ
ＱＷＫＶＤＮＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤＳＴＹＳＬＳＳＴＬＴＬＳＫＡ
ＤＹＥＫＨＫＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳＦＮＲＧＥＣ

[図5]

配列番号５：抗ＴＲＯＰ２抗体重鎖のアミノ酸配列

ＭＫＨＬＷＦＦＬＬＬＶＡＡＰＲＷＶＬＳＱＶＱＬＶＱＳＧＡＥＶＫＫＰＧＡＳＶＫ
ＶＳＣＫＡＳＧＹＴＦＴＴＡＧＭＱＷＶＲＱＡＰＧＱＧＬＥＷＭＧＷＩＮＴＨＳＧＶ
ＰＫＹＡＥＤＦＫＧＲＶＴＩＳＡＤＴＳＴＳＴＡＹＬＱＬＳＳＬＫＳＥＤＴＡＶＹＹ
ＣＡＲＳＧＦＧＳＳＹＷＹＦＤＶＷＧＱＧＴＬＶＴＶＳＳＡＳＴＫＧＰＳＶＦＰＬＡ
ＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹＦＰＥＰＶＴＶＳＷＮＳＧＡＬＴＳＧＶ
ＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴＶＰＳＳＳＬＧＴＱＴＹＩＣＮＶＮＨＫ
ＰＳＮＴＫＶＤＫＲＶＥＰＫＳＣＤＫＴＨＴＣＰＰＣＰＡＰＥＬＬＧＧＰＳＶＦＬＦ
ＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶＶＤＶＳＨＥＤＰＥＶＫＦＮＷＹＶＤＧ
ＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲＶＶＳＶＬＴＶＬＨＱＤＷＬＮＧＫＥＹ
ＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡＫＧＱＰＲＥＰＱＶＹＴＬＰＰＳＲＥＥ
ＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩＡＶＥＷＥＳＮＧＱＰＥＮＮＹＫＴＴＰ
ＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳＲＷＱＱＧＮＶＦＳＣＳＶＭＨＥＡＬＨ
ＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

シグナル配列（１－１９）、可変領域（２０－１４０）、定常領域（１４１－４７０）

[図6]

配列番号６：抗ＴＲＯＰ２抗体軽鎖のアミノ酸配列

ＭＶＬＱＴＱＶＦＩＳＬＬＬＷＩＳＧＡＹＧＤＩＱＭＴＱＳＰＳＳＬＳＡＳＶＧＤＲ
ＶＴＩＴＣＫＡＳＱＤＶＳＴＡＶＡＷＹＱＱＫＰＧＫＡＰＫＬＬＩＹＳＡＳＹＲＹＴ
ＧＶＰＳＲＦＳＧＳＧＳＧＴＤＦＴＬＴＩＳＳＬＱＰＥＤＦＡＶＹＹＣＱＱＨＹＩＴ
ＰＬＴＦＧＱＧＴＫＬＥＩＫＲＴＶＡＡＰＳＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶ
ＶＣＬＬＮＮＦＹＰＲＥＡＫＶＱＷＫＶＤＮＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤ
ＳＴＹＳＬＳＳＴＬＴＬＳＫＡＤＹＥＫＨＫＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳ
ＦＮＲＧＥＣ

シグナル配列（１－２０）、可変領域（２１－１２９）、定常領域（１３０－２３４）

[図7]

配列番号７：抗Ｂ７－Ｈ３抗体重鎖のアミノ酸配列

ＭＫＨＬＷＦＦＬＬＬＶＡＡＰＲＷＶＬＳＱＶＱＬＶＱＳＧＡＥＶＫＫＰＧＳＳＶＫ
ＶＳＣＫＡＳＧＹＴＦＴＮＹＶＭＨＷＶＲＱＡＰＧＱＧＬＥＷＭＧＹＩＮＰＹＮＤＤ
ＶＫＹＮＥＫＦＫＧＲＶＴＩＴＡＤＥＳＴＳＴＡＹＭＥＬＳＳＬＲＳＥＤＴＡＶＹＹ
ＣＡＲＷＧＹＹＧＳＰＬＹＹＦＤＹＷＧＱＧＴＬＶＴＶＳＳＡＳＴＫＧＰＳＶＦＰＬ
ＡＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹＦＰＥＰＶＴＶＳＷＮＳＧＡＬＴＳＧ
ＶＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴＶＰＳＳＳＬＧＴＱＴＹＩＣＮＶＮＨ
ＫＰＳＮＴＫＶＤＫＲＶＥＰＫＳＣＤＫＴＨＴＣＰＰＣＰＡＰＥＬＬＧＧＰＳＶＦＬ
ＦＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶＶＤＶＳＨＥＤＰＥＶＫＦＮＷＹＶＤ
ＧＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲＶＶＳＶＬＴＶＬＨＱＤＷＬＮＧＫＥ
ＹＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡＫＧＱＰＲＥＰＱＶＹＴＬＰＰＳＲＥ
ＥＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩＡＶＥＷＥＳＮＧＱＰＥＮＮＹＫＴＴ
ＰＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳＲＷＱＱＧＮＶＦＳＣＳＶＭＨＥＡＬ
ＨＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

シグナル配列（１－１９）、可変領域（２０－１４１）、定常領域（１４２－４７１）

[図8]

配列番号８：抗Ｂ７－Ｈ３抗体軽鎖のアミノ酸配列

ＭＶＬＱＴＱＶＦＩＳＬＬＬＷＩＳＧＡＹＧＥＩＶＬＴＱＳＰＡＴＬＳＬＳＰＧＥＲ
ＡＴＬＳＣＲＡＳＳＲＬＩＹＭＨＷＹＱＱＫＰＧＱＡＰＲＰＬＩＹＡＴＳＮＬＡＳＧ
ＩＰＡＲＦＳＧＳＧＳＧＴＤＦＴＬＴＩＳＳＬＥＰＥＤＦＡＶＹＹＣＱＱＷＮＳＮＰ
ＰＴＦＧＱＧＴＫＶＥＩＫＲＴＶＡＡＰＳＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶＶ
ＣＬＬＮＮＦＹＰＲＥＡＫＶＱＷＫＶＤＮＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤＳ
ＴＹＳＬＳＳＴＬＴＬＳＫＡＤＹＥＫＨＫＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳＦ
ＮＲＧＥＣ

シグナル配列（１－２０）、可変領域（２１－１２８）、定常領域（１２９－２３３）

[図9]

配列番号９：抗ＧＰＲ２０抗体重鎖のアミノ酸配列

ＭＫＨＬＷＦＦＬＬＬＶＡＡＰＲＷＶＬＳＥＶＱＬＶＱＳＧＡＥＶＫＫＰＧＡＳＶＫ
ＶＳＣＫＡＳＧＹＴＦＴＳＹＹＩＳＷＩＲＱＡＰＧＱＧＬＫＹＭＧＦＩＮＰＧＳＧＨ
ＴＮＹＮＥＫＦＫＧＲＶＴＩＴＡＤＫＳＳＳＴＡＴＭＥＬＳＳＬＲＳＥＤＴＡＶＹＹ
ＣＡＲＧＡＧＧＦＬＲＩＩＴＫＦＤＹＷＧＱＧＴＬＶＴＶＳＳＡＳＴＫＧＰＳＶＦＰ
ＬＡＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹＦＰＥＰＶＴＶＳＷＮＳＧＡＬＴＳ
ＧＶＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴＶＰＳＳＳＬＧＴＱＴＹＩＣＮＶＮ
ＨＫＰＳＮＴＫＶＤＫＲＶＥＰＫＳＣＤＫＴＨＴＣＰＰＣＰＡＰＥＬＬＧＧＰＳＶＦ
ＬＦＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶＶＤＶＳＨＥＤＰＥＶＫＦＮＷＹＶ
ＤＧＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲＶＶＳＶＬＴＶＬＨＱＤＷＬＮＧＫ
ＥＹＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡＫＧＱＰＲＥＰＱＶＹＴＬＰＰＳＲ
ＥＥＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩＡＶＥＷＥＳＮＧＱＰＥＮＮＹＫＴ
ＴＰＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳＲＷＱＱＧＮＶＦＳＣＳＶＭＨＥＡ
ＬＨＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

シグナル配列（１－１９）、可変領域（２０－１４２）、定常領域（１４３－４７２）

[図10]

配列番号１０：抗ＧＰＲ２０抗体軽鎖のアミノ酸配列

ＭＶＬＱＴＱＶＦＩＳＬＬＬＷＩＳＧＡＹＧＤＴＱＬＴＱＳＰＳＳＬＳＡＳＶＧＤＲ
ＶＴＩＴＣＲＡＳＫＳＶＳＴＹＩＨＷＹＱＱＫＰＧＫＱＰＫＬＬＩＹＳＡＧＮＬＥＳ
ＧＶＰＳＲＦＳＧＳＧＳＧＴＤＦＴＬＴＩＳＳＬＱＰＥＤＦＡＮＹＹＣＱＱＩＮＥＬ
ＰＹＴＦＧＱＧＴＫＶＥＩＫＲＴＶＡＡＰＳＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶ
ＶＣＬＬＮＮＦＹＰＲＥＡＫＶＱＷＫＶＤＮＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤ
ＳＴＹＳＬＳＳＴＬＴＬＳＫＡＤＹＥＫＨＫＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳ
ＦＮＲＧＥＣ

シグナル配列（１－２０）、可変領域（２１－１２９）、定常領域（１３０－２３４）

[図11]

配列番号１１：抗ＣＤＨ６抗体重鎖のアミノ酸配列

ＭＫＨＬＷＦＦＬＬＬＶＡＡＰＲＷＶＬＳＥＶＱＬＶＱＳＧＡＥＶＫＫＰＧＡＳＶＫ
ＶＳＣＫＡＳＧＹＴＦＴＲＮＦＭＨＷＶＲＱＡＰＧＱＧＬＥＷＭＧＷＩＹＰＧＤＧＥ
ＴＥＹＡＱＫＦＱＧＲＶＴＩＴＡＤＴＳＴＳＴＡＹＭＥＬＳＳＬＲＳＥＤＴＡＶＹＹ
ＣＡＲＧＶＹＧＧＦＡＧＧＹＦＤＦＷＧＱＧＴＬＶＴＶＳＳＡＳＴＫＧＰＳＶＦＰＬ
ＡＰＳＳＫＳＴＳＧＧＴＡＡＬＧＣＬＶＫＤＹＦＰＥＰＶＴＶＳＷＮＳＧＡＬＴＳＧ
ＶＨＴＦＰＡＶＬＱＳＳＧＬＹＳＬＳＳＶＶＴＶＰＳＳＳＬＧＴＱＴＹＩＣＮＶＮＨ
ＫＰＳＮＴＫＶＤＫＲＶＥＰＫＳＣＤＫＴＨＴＣＰＰＣＰＡＰＥＬＬＧＧＰＳＶＦＬ
ＦＰＰＫＰＫＤＴＬＭＩＳＲＴＰＥＶＴＣＶＶＶＤＶＳＨＥＤＰＥＶＫＦＮＷＹＶＤ
ＧＶＥＶＨＮＡＫＴＫＰＲＥＥＱＹＮＳＴＹＲＶＶＳＶＬＴＶＬＨＱＤＷＬＮＧＫＥ
ＹＫＣＫＶＳＮＫＡＬＰＡＰＩＥＫＴＩＳＫＡＫＧＱＰＲＥＰＱＶＹＴＬＰＰＳＲＥ
ＥＭＴＫＮＱＶＳＬＴＣＬＶＫＧＦＹＰＳＤＩＡＶＥＷＥＳＮＧＱＰＥＮＮＹＫＴＴ
ＰＰＶＬＤＳＤＧＳＦＦＬＹＳＫＬＴＶＤＫＳＲＷＱＱＧＮＶＦＳＣＳＶＭＨＥＡＬ
ＨＮＨＹＴＱＫＳＬＳＬＳＰＧＫ

シグナル配列（１－１９）、可変領域（２０－１４１）、定常領域（１４２－４７１）


[図12]

配列番号１２：抗ＣＤＨ６抗体軽鎖のアミノ酸配列


ＭＶＬＱＴＱＶＦＩＳＬＬＬＷＩＳＧＡＹＧＤＩＱＭＴＱＳＰＳＳＬＳＡＳＶＧＤＲ
ＶＴＩＴＣＫＡＳＱＮＩＹＫＮＬＡＷＹＱＱＫＰＧＫＡＰＫＬＬＩＹＤＡＮＴＬＱＴ
ＧＶＰＳＲＦＳＧＳＧＳＧＳＤＦＴＬＴＩＳＳＬＱＰＥＤＦＡＴＹＦＣＱＱＹＹＳＧ
ＷＡＦＧＱＧＴＫＶＥＩＫＲＴＶＡＡＰＳＶＦＩＦＰＰＳＤＥＱＬＫＳＧＴＡＳＶＶ
ＣＬＬＮＮＦＹＰＲＥＡＫＶＱＷＫＶＤＮＡＬＱＳＧＮＳＱＥＳＶＴＥＱＤＳＫＤＳ
ＴＹＳＬＳＳＴＬＴＬＳＫＡＤＹＥＫＨＫＶＹＡＣＥＶＴＨＱＧＬＳＳＰＶＴＫＳＦ
ＮＲＧＥＣ

シグナル配列（１－２０）、可変領域（２１－１２８）、定常領域（１２９－２３３）


[図13]


Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
7
14
21
Days
Control
HER2-ADC (1)
Olaparib
Combination
***
*** P<0.0001 (Dunnett's test)


[図14]


Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
7
14
21
Days
Control
HER2-ADC (1)
Talazoparib
Combination
***
*** P<0.0001 (Dunnett's test)


[図15]


Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
7
14
21
Days
Control
HER2-ADC (1)
Niraparib
Combination
***
*** P=0.0001 (Dunnett's test)


[図16]


Tumor volume (mm3)
1200
1000
800
600
400
200
0
0
7
14
21
Days
***
Control
HER2-ADC (1)
Rucaparib
Combination
*** P<0.0001 (Dunnett's test)


[図17]


Tumor volume (mm3)
1800
1500
1200
900
600
300
0
0
7
14
21
28
35
Days
***
Control
HER2-ADC (1)
Olaparib
Combination
*** P<0.0001 (Dunnett's test)


[図18]


Tumor volume (mm3)
1800
1500
1200
900
600
300
0
0
7
14
21
28
35
Days
***
Control
HER2-ADC (1)
Talazoparib
Combination
*** P<0.0001 (Dunnett's test)


[図19]


Tumor volume (mm3)
1800
1500
1200
900
600
300
0
0
7
14
21
28
35
Days
***
Control
HER2-ADC (1)
Rucaparib
Combination
*** P=0.0002 (Dunnett's test)


[図20]


Tumor volume (mm3)
1500
1200
900
600
300
0
0
7
14
21
28
Days
Control
HER2-ADC (1)
Olaparib
Combination


[図21]


Tumor volume (mm3)
1500
1200
900
600
300
0
0
7
14
21
28
Days
***
*
Control
HER2-ADC (1)
Talazoparib
Combination
* P<0.05, *** P<0.0001 (Dunnett's test)


[図22]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
Days
Control
HER2-ADC (1)
Olaparib
Combination
*
* P<0.05 (Dunnett's test)


[図23]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
Days
***
*
Control
HER2-ADC (1)
Talazoparib
Combination
* P<0.05, *** P=0.0004 (Dunnett's test)


[図24]


Tumor volume (mm3)
2000
1600
1200
800
400
0
0
7
14
21
28
35
Days
***
***
Control
HER2-ADC (1)
Olaparib
Combination
*** P<0.001 (Dunnett's test)


[図25]


2000
1600
1200
800
400
0
Tumor volume (mm3)
0
7
14
21
28
35
Days
Control
HER2-ADC (1)
Talazoparib
Combination
***
***
*** P<0.001 (Dunnett's test)


[図26]


2000
1600
1200
800
400
0
Tumor volume (mm3)
0
7
14
21
28
Days
Control
HER3-ADC (1)
Olaparib
Combination
***
**
** P<0.01, *** P<0.001 (Dunnett's test)


[図27]


2000
1600
1200
800
400
0
Tumor volume (mm3)
0
7
14
21
28
Days
Control
HER3-ADC (1)
Talazoparib
Combination
***
***
*** P<0.001 (Dunnett's test)


[図28]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
28
Days
Control
HER3-ADC (1)
Olaparib
Combination
***
*** P<0.001 (Dunnett's test)


[図29]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
7
14
21
28
Days
Control
HER3-ADC (1)
Talazoparib
Combination
***
*** P<0.001 (Dunnett's test)


[図30]


Tumor volume (mm3)
3000
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days
Control
TROP2-ADC (1)
Olaparib
Combination


[図31]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days
Control
TROP2-ADC (1)
Rucaparib
Combination
***
*** P<0.0001 (Dunnett's test)


[図32]


Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
20
25
Days
Control
TROP2-ADC (1)
Talazoparib
Combination
***
*
*** P<0.0001, * P<0.05 (Dunnett's test)


[図33]


Tumor volume(mm3)
2500
2000
1500
1000
500
0
0
7
14
Days
***
Control
CDH6-ADC(1)
Talazoparib
Combination
*** P=0.0004 (Dunnett's test)


[図34]


Tumor volume(mm3)
2500
2000
1500
1000
500
0
0
7
14
Days
**
Control
CDH6-ADC(1)
Rucaparib
Combination
** P=0.004 (Dunnett's test)


[図35]


Tumor volume(mm3)
2500
2000
1500
1000
500
0
0
7
14
Days
**
Control
CDH6-ADC(1)
Niraparib
Combination
** P=0.0025 (Dunnett's test)

[図36]


Tumor volume(mm3)
2500
2000
1500
1000
500
0
0
7
14
Days
**
Control
CDH6-ADC(1)
Veriparib
Combination
** P=0. 0013 (Dunnett's test)

[図37]


2500
2000
1500
1000
500
0
Tumor volume(mm3)
0
7
14
Days
**
Control
CDH6-ADC(1)
Olaparib
Combination
** P=0.0025 (Dunnett's test)